Mizuho Securities analyst Anthony Petrone maintains $Abbott Laboratories (ABT.US)$ with a hold rating, and adjusts the target price from $115 to $130.
According to TipRanks data, the analyst has a success rate of 51.6% and a total average return of 8.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Abbott Laboratories (ABT.US)$'s main analysts recently are as follows:
Abbott's recent modest sales and earnings per share surpassing expectations has reinforced beliefs in the company's capacity to maintain double-digit sales growth in its MedTech division for an extended period, as well as high single-digit growth in total sales. The enduring growth trajectory of Abbott's MedTech business is thought to be undervalued, and the company is considered to present a prime opportunity for high single to low double-digit sales expansion.
Following the Q3 results, Abbott is perceived to be in a strong position to cope with any competitive pressures from pulsed field ablation, and the prospect of leadless pacing could potentially enhance the growth of cardiac rhythm management to exceed 3%. Despite the firm's solid operational execution and favorable circumstances, it's assessed that current market expectations are aligned, and the company's valuation is considered reasonable when compared to its peers.
Following Abbott's third-quarter report, the expectation is set on the company to demonstrate enduring operating margin growth after the conclusion of Testing activities, as per an analyst's commentary.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
瑞穗證券分析師Anthony Petrone維持$雅培 (ABT.US)$持有評級,並將目標價從115美元上調至130美元。
根據TipRanks數據顯示,該分析師近一年總勝率為51.6%,總平均回報率為8.4%。
此外,綜合報道,$雅培 (ABT.US)$近期主要分析師觀點如下:
雅培最近溫和的銷售額和每股收益超出預期,這增強了人們的信心,即該公司有能力長期保持其醫療技術部門的兩位數銷售增長,以及總銷售額的個位數高增長。雅培醫療科技業務的持續增長軌跡被認爲被低估了,該公司被認爲是實現高單位數至低兩位數銷售增長的絕佳機會。
根據第三季度的業績,雅培被認爲有能力應對脈衝場消融帶來的任何競爭壓力,無導線起搏的前景有可能將心律管理的增長提高到3%以上。儘管該公司的運營執行力穩健,環境良好,但據評估,當前的市場預期是一致的,與同行相比,該公司的估值被認爲是合理的。
根據一位分析師的評論,繼雅培發佈第三季度報告之後,預計該公司將在測試活動結束後表現出持續的營業利潤率增長。
提示:
TipRanks為獨立第三方,提供金融分析師的分析數據,並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議,僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級,分析師星級代表分析師所有推薦的過往表現,通過分析師的總勝率和平均回報率综合計算得出,星星越多,則該分析師過往表現越優異,最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否,取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合,並根據評級變化對組合進行調整,在近一年中該投資組合所獲得的回報率。